157 related articles for article (PubMed ID: 9408607)
1. In vitro and in vivo characteristics of human squamous cell carcinoma of the head and neck cells engineered to secrete interleukin-2.
Nagashima S; Reichert TE; Kashii Y; Suminami Y; Chikamatsu K; Whiteside TL
Cancer Gene Ther; 1997; 4(6):366-76. PubMed ID: 9408607
[TBL] [Abstract][Full Text] [Related]
2. Role of cytokines in the adoptive immunotherapy of an experimental model of human head and neck cancer by human IL-2-activated natural killer cells.
Rabinowich H; Vitolo D; Altarac S; Herberman RB; Whiteside TL
J Immunol; 1992 Jul; 149(1):340-9. PubMed ID: 1535088
[TBL] [Abstract][Full Text] [Related]
3. Local adoptive immunotherapy of human head and neck cancer xenografts in nude mice with lymphokine-activated killer cells and interleukin 2.
Sacchi M; Snyderman CH; Heo DS; Johnson JT; d'Amico F; Herberman RB; Whiteside TL
Cancer Res; 1990 May; 50(10):3113-8. PubMed ID: 2334906
[TBL] [Abstract][Full Text] [Related]
4. Enrichment in tumor-reactive CD8+ T-lymphocytes by positive selection from the blood and lymph nodes of patients with head and neck cancer.
Letessier EM; Heo DS; Okarma T; Johnson JT; Herberman RB; Whiteside TL
Cancer Res; 1991 Aug; 51(15):3891-9. PubMed ID: 1677310
[TBL] [Abstract][Full Text] [Related]
5. Systemic administration of recombinant interleukin-6 in mice induces proliferation of lymphoid cells in vivo.
Puri RK; Leland P
Lymphokine Cytokine Res; 1992 Jun; 11(3):133-9. PubMed ID: 1391232
[TBL] [Abstract][Full Text] [Related]
6. Biology, cytogenetics, and sensitivity to immunological effector cells of new head and neck squamous cell carcinoma lines.
Heo DS; Snyderman C; Gollin SM; Pan S; Walker E; Deka R; Barnes EL; Johnson JT; Herberman RB; Whiteside TL
Cancer Res; 1989 Sep; 49(18):5167-75. PubMed ID: 2766286
[TBL] [Abstract][Full Text] [Related]
7. Receptors for interleukin 2 on human squamous cell carcinoma cell lines and tumor in situ.
Weidmann E; Sacchi M; Plaisance S; Heo DS; Yasumura S; Lin WC; Johnson JT; Herberman RB; Azzarone B; Whiteside TL
Cancer Res; 1992 Nov; 52(21):5963-70. PubMed ID: 1394222
[TBL] [Abstract][Full Text] [Related]
8. [Interleukin-2 and LAK cells in the local immunotherapy of tumors of the head and neck: an experimental model].
Sacchi M; Johnson JT; Whiteside TL; Cortesina G
Acta Otorhinolaryngol Ital; 1989; 9(4):391-8. PubMed ID: 2618654
[TBL] [Abstract][Full Text] [Related]
9. Long-term interleukin 2-dependent growth and cytotoxic activity of tumor-infiltrating lymphocytes from human squamous cell carcinomas of the head and neck.
Heo DS; Whiteside TL; Johnson JT; Chen KN; Barnes EL; Herberman RB
Cancer Res; 1987 Dec; 47(23):6353-62. PubMed ID: 3315186
[TBL] [Abstract][Full Text] [Related]
10. IFN-beta 2/IL-6 augments the activity of human natural killer cells.
Luger TA; Krutmann J; Kirnbauer R; Urbanski A; Schwarz T; Klappacher G; Köck A; Micksche M; Malejczyk J; Schauer E
J Immunol; 1989 Aug; 143(4):1206-9. PubMed ID: 2787359
[TBL] [Abstract][Full Text] [Related]
11. A mechanism by which human breast carcinoma cells escape the host immune system.
Hakim AA
Neoplasma; 1988; 35(6):691-705. PubMed ID: 3265486
[TBL] [Abstract][Full Text] [Related]
12. [Adoptive immunotherapy by intra-arterial infusion of ATLAK or Allo-TLAK cells in patients with head and neck cancer].
Ikawa T; Eura M; Fukiage T; Murakami H; Yamasaki S; Fukuda K; Fukushima M; Arishima S; Maehara T; Ishikawa T
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1438-47. PubMed ID: 2786378
[TBL] [Abstract][Full Text] [Related]
13. Expression of the tumor necrosis factor gene in tumor cells correlates with reduced tumorigenicity and reduced invasiveness in vivo.
Vanhaesebroeck B; Mareel M; Van Roy F; Grooten J; Fiers W
Cancer Res; 1991 Apr; 51(8):2229-38. PubMed ID: 2009541
[TBL] [Abstract][Full Text] [Related]
14. Impairment of natural killer functions by interleukin 6 increases lymphoblastoid cell tumorigenicity in athymic mice.
Tanner J; Tosato G
J Clin Invest; 1991 Jul; 88(1):239-47. PubMed ID: 1647416
[TBL] [Abstract][Full Text] [Related]
15. Lymphokine-activated killing of autologous and allogeneic short-term cultured head and neck squamous carcinomas.
Leess FR; Bredenkamp JK; Lichtenstein A; Mickel RA
Laryngoscope; 1989 Dec; 99(12):1255-61. PubMed ID: 2601539
[TBL] [Abstract][Full Text] [Related]
16. Characterization and growth factor requirements of SJL lymphomas. I. Development of a B cell growth factor-dependent in vitro cell line, cRCS-X.
Lasky JL; Ponzio NM; Thorbecke GJ
J Immunol; 1988 Jan; 140(2):679-87. PubMed ID: 3275720
[TBL] [Abstract][Full Text] [Related]
17. Perilymphatic injections of recombinant interleukin-2 (rIL-2) partially correct the immunologic defects in patients with advanced head and neck squamous cell carcinoma.
Melioli G; Margarino G; Scala M; Mereu P; Bertoglio S; Schenone G; Barbaresi M; Machí AM; Santi L; Badellino F
Laryngoscope; 1992 May; 102(5):572-8. PubMed ID: 1533435
[TBL] [Abstract][Full Text] [Related]
18. Clonal heterogeneity of a human functioning tumor which produces granulocyte colony-stimulating factor.
Okabe T; Kasuga T
Jpn J Clin Oncol; 1990 Dec; 20(4):349-55. PubMed ID: 1704443
[TBL] [Abstract][Full Text] [Related]
19. Expression of an exogenous tumor necrosis factor (TNF) gene in TNF-sensitive cell lines confers resistance to TNF-mediated cell lysis.
Vanhaesebroeck B; Decoster E; Van Ostade X; Van Bladel S; Lenaerts A; Van Roy F; Fiers W
J Immunol; 1992 May; 148(9):2785-94. PubMed ID: 1374099
[TBL] [Abstract][Full Text] [Related]
20. Cytotoxic drug sensitivity of squamous cell carcinoma as predicted by an in vitro testing model.
Elprana D; Schwachöfer J; Kuijpers W; Van Den Broek P; Wagener DJ
Anticancer Res; 1989; 9(4):1089-94. PubMed ID: 2479326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
